OccuRx

OccuRx Pty Ltd, a clinical-stage biopharmaceutical company, was established in Melbourne, Australia, in 2014, focusing on developing treatments for diseases linked to inflammation and fibrosis. The company was founded by Professor Darren Kelly, a distinguished figure in translational medicine with over two decades of experience in the life sciences and biotech sectors. His journey from academia to entrepreneurship was driven by a desire to translate his extensive research on cardiovascular disease and fibrosis into tangible patient therapies. This ambition earlier led him to establish Fibrotech Therapeutics, which was acquired by Shire Plc in a significant deal. The ocular assets from that venture were carved out to form OccuRx.

The company's core business revolves around the development of small-molecule drugs that target a novel G protein-coupled receptor (GPCR), specifically GPR68, which is considered a 'master switch' for fibrosis. This positions OccuRx in the specialty pharmaceuticals market, addressing significant unmet needs in fibrotic diseases, an area responsible for an estimated 45% of all deaths globally and representing a market exceeding $15 billion annually. The business model is typical of a clinical-stage biotech firm, centered on research and development funded by venture capital. Revenue generation is anticipated through partnerships with larger pharmaceutical companies or eventual commercialization of its drug candidates. OccuRx has successfully raised capital through several funding rounds, including a notable $16 million Series B in 2022, co-led by Brandon BioCatalyst and Uniseed, to advance its clinical programs.

OccuRx's lead product candidate is OCX-063, an oral therapy designed to treat and prevent fibrosis. Having successfully completed a Phase 1 clinical trial, OCX-063 is now being progressed into clinical studies for Chronic Kidney Disease (CKD) and focal segmental glomerulosclerosis (FSGS), a rare kidney disease. The therapy's potential extends to various fibrotic conditions affecting major organs like the eye, lung, and skin. Initially focused on ocular diseases like diabetic retinopathy, the company strategically pivoted towards CKD due to more favorable clinical trial endpoints. In a strategic consolidation, OccuRx was acquired by Certa Therapeutics in December 2024, another company founded by Professor Kelly. This merger combined their complementary assets and expertise, creating a stronger pipeline of GPR68 inhibitors aimed at tackling fibrotic diseases.

Keywords: fibrosis treatment, inflammation therapy, clinical-stage biopharmaceutical, GPR68 inhibitor, chronic kidney disease, OCX-063, Darren Kelly, small-molecule drugs, orphan diseases, drug development, venture capital, Certa Therapeutics, Brandon BioCatalyst, Uniseed, translational medicine, anti-fibrotic therapies, renal fibrosis, focal segmental glomerulosclerosis, ocular disease, biopharma acquisition